EXCLUSIVE: EMA looks into Indian clinical trials following NIH halts
This article was originally published in Scrip
Executive Summary
Following recent reports that the US government had stopped clinical trials it was sponsoring in India due to concerns over new regulations in the country, the European Medicines Agency has confirmed that it has "approached the Indian drug controller to learn more about these issues and any possible implication on trials to be included in European applications."
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.
EU CHMP Opinions And MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.